Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
9 reports, 6 independent
Updated Aug 30
Gone quiet
Reached 6 outlets in its first 24 hours
- Reports
- 9
- Developments
- 5
- Repetition
- 44%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Royalty Pharma acquired royalty rights in Amgen's Imdelltra.1 source
Royalty Pharma acquired rights to Amgen's cancer drug.1 source
Royalty Pharma secured a $2B partnership with Revolution Medicines alongside its acquisition of Amgen's Imdelltra royalty.1 source
Royalty Pharma gains access to Amgen's drug sales.1 source
Imdelltra received accelerated FDA approval following the royalty deal between Royalty Pharma and Amgen.1 source
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Royalty Pharma
biopharmaceutical company based in New York City
Related events
- GSK and Amgen are major biopharma players.
- Amgen acquired Horizon Therapeutics, a company whose portfolio included a drug discovered by AstraZeneca.
- Joint drug trial success boosts Amgen stock.
- Pablo Legorreta was named the founder and CEO of Royalty Pharma, which provides funding in exchange for royalty rights.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
Coverage
Newest first; wire copies grouped- Insider MonkeyRoyalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase Royalty Pharma plc (NASDAQ:RPRX) is one of the most undervalued and overlooked large-cap stocks. On August 25, Royalty Ph
- Simply Wall St.Does Imdelltra Royalty Deal Reinforce Royalty Pharma’s Long-Term Asset Strategy (RPRX)? Royalty Pharma announced it has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for US$88
- Insider MonkeyRoyalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Royalty Pharma plc is one of th
- Insider MonkeyRoyalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Royalty Pharma plc is one of them. Roy
- Simply Wall St.Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra Royalty Pharma recently acquired a royalty interest in Amgen's Imdelltra, a move that may have added confidence to
- BioPharma DiveRoyalty Pharma buys BeOne stake in Amgen lung cancer drug sales This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive n
- GlobeNewswireRoyalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC
- Business WireBeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales
- ReutersRoyalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug (Reuters) -Royalty Pharma has agreed to buy a royalty interest in Amgen's drug for small cell lung cancer from BeO